NDA 021090 · Aspen Global INC
Cyclessa
Desogestrel, Ethinyl Estradiol · Oral-28
Last checked: Nov 20, 2026Latest source record: Apr 29, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2000
Dec 20, 2000
Approved uses
1
Original approval plus efficacy supplements
Registered trials
59
14 Phase 3, 3 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 20, 2000 Original approval · Type 3 - New Dosage Form Review
1 products under this application
- CYCLESSA · DESOGESTREL 0.1MG,0.125MG,0.15MG; ETHINYL ESTRADIOL 0.025MG,0.025MG,0.025MG · TABLET, ORAL-28 · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Desogestrel" as an intervention, any sponsor and status, largest first.
- A Study to Evaluate the Efficacy and Safety of DR-102 for the Prevention of PregnancyPivotal-lookingCompleted
Teva Branded Pharmaceutical Products R&D, Inc.Teva (TEVA)
NCT01178125 · 2,858 participants · Start Aug 2010 · Primary completion Jan 2013
Drug: DR-102 · For: Contraception; Female Contraception
Sites: Montgomery, Alabama; Phoenix, Arizona; Little Rock, Arkansas · 62 sites in all
- A Study of Efficacy and Safety With the Transdermal Contraceptive System Versus Mercilon.Pivotal-lookingCompleted
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Johnson & Johnson (Janssen) (JNJ)
NCT00236782 · 1,517 participants · Start Oct 1997
Drug: norelgestromin + ethinyl estradiol; mercilon · For: Contraception
- A Clinical Study on Yasmin® vs. Marvelon® in Chinese Women Requiring ContraceptionPivotal-lookingCompleted
BayerBayer (BAYRY)
NCT00185419 · 842 participants · Start Nov 2003 · Primary completion Mar 2006
Drug: Yasmin; Marvelon · For: Contraception
Sites: Ask Contact, China
Yale UniversityAcademic, hospital or other
NCT06334315 · 700 participants (planned) · Start Oct 29, 2024 · Primary completion May 2028
Drug: Desogestrel / Ethinyl Estradiol Pill · For: Contraception; Pharmacogenomic Drug Interaction
Sites: Aurora, Colorado; New Haven, Connecticut
- Comparative Trial in Hormone Withdrawal Associated SymptomsPivotal-lookingCompleted
BayerBayer (BAYRY)
NCT01076582 · 592 participants · Start Apr 2010 · Primary completion Oct 2011
Drug: EE20/DRSP (YAZ, BAY86-5300); Ethinylestradiol (EE) and desogestrel (DSG) (Mercilon) · For: Oral Contraceptive
Sites: Buenos Aires, Argentina; Rosario, Argentina; Santiago, Chile · 44 sites in all
- Traditional Chinese Medicine, Western Medicine and Low-level Light Therapy(LLLT) for Primary Dysmenorrhea(PD)Pivotal-lookingStatus unknown
Peking Union Medical College HospitalAcademic, hospital or other
NCT03953716 · 480 participants (planned) · Start Jun 22, 2019 · Primary completion Jun 30, 2020
Drug: DING KUN DAN; Simulated drug of DING KUN DAN and 1 more · For: Primary Dysmenorrhea; Traditional Chinese Medicine; Light
Sites: Beijing, China
- Yasmin 20 Cycle Control - Yasmin 20 Versus Mercilon in Healthy Female VolunteersPivotal-lookingCompleted
BayerBayer (BAYRY)
NCT00624130 · 453 participants · Start Mar 2004
Drug: Yasmin 20; Mercilon · For: Contraception
Sites: Horn, Austria; Leibnitz, Styria, Austria; Mödling, Austria · 17 sites in all
- Predictive Factors for Ovarian Stimulation Using a Fixed Daily Dose of 200 IU Recombinant FSH (Study 142003)(P05696)Pivotal-lookingCompleted
Organon and CoIndustry
NCT00778999 · 442 participants · Start Oct 1, 2006 · Primary completion Jul 24, 2008
Drug: Marvelon · For: Infertility
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Combined oral contraceptives: venous thrombosis.
de Bastos M, Stegeman BH, Rosendaal FR, et al. · Cochrane Database Syst Rev 2014 · Research Support, Non-U.S. Gov't, Systematic Review
- Hormonal contraception in women with endometriosis: a systematic review.
Grandi G, Barra F, Ferrero S, et al. · Eur J Contracept Reprod Health Care 2019 · Systematic Review
- Comparative effectiveness and safety of different progestins in combined oral contraceptives: a systematic review and network meta-analysis of randomized controlled trials.
Li B, Xu X, Xu K, et al. · Arch Gynecol Obstet 2025 · Comparative Study, Network Meta-Analysis
- Association of Hormonal Contraceptive Use With Adverse Health Outcomes: An Umbrella Review of Meta-analyses of Randomized Clinical Trials and Cohort Studies.
Brabaharan S, Veettil SK, Kaiser JE, et al. · JAMA Netw Open 2022 · Systematic Review
- Progestin-only pills for contraception.
Grimes DA, Lopez LM, O'Brien PA, et al. · Cochrane Database Syst Rev 2013 · Meta-Analysis, Research Support, N.I.H., Extramural
- Progestin-only contraceptives: effects on weight.
Lopez LM, Ramesh S, Chen M, et al. · Cochrane Database Syst Rev 2016 · Research Support, N.I.H., Extramural, Research Support, U.S. Gov't, Non-P.H.S.
Sponsor: Aspen Global INC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.